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Introduction 
Diabetes mellitus (DM) integrates a heterogeneous group of metabolic disorders characterized by the body’s inability to maintain glucose homeostasis. 
Actually, this public health problem affected 425 million people in world, or 8.8% of adults from 20-79 years. The number increases to 451 million if the 
age is expanded to 18-99 years. If these trends continue, by 2045, 693 million people will have diabetes. The centrality of the patient’s role in self-
administered health care management is a crucial topic today as we focus on issues of adherence to the treatment of diabetes. In short, adherence to 
treatment does not imply simply the scrupulous following of the medical regimen; it also entails engaging in several health-related behaviours, such as 
eating behaviour or physical activity.  
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 Methods: A descriptive correlational study with cross-sectional design was 
conducted. Patients attending diabetes consultations participated in the study (N = 
347). Participants completed the Beck Depression Inventory (BDI) and adherence 
was established based on HbA1c criteria.  
Results: The mean score on the BDI, for either DM type 1 (M = 7.74; SD = 6.62) 
and type 2 (M = 9.38 ; SD = 8.62), is higher than in general population (GP) (M = 
3.87; SD = 4.15). Mean comparisons between DM type 1 and GP as well as 
between DM type 2 and GP are statistically significant (t = 6.183; p < .001; t = 8.47; 
p < .001). The association between depression and adherence was significant in 
both types of DM (X2 = 5.86; p = .015; X2  = 6.57; p = .010). DM type 1 and type 2 
participants exhibit significant differences in the symptoms related to inability to 
work (“O”), sleep disturbances (“P”), fatigue (“Q”), weight loss (“S”), and loss of 
libido (“U”). Post-hoc tests revealed that median scores of these symptoms are 
lower for DM type 1 as compared to DM type 2. 
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Conclusions: The current study sought out to contribute to increase understanding 
of the relationship between diabetes mellitus and depression. In this context, it is 
important to highlight the distinction between depressive symptoms and the 
physical consequences inherent to Type 2 diabetes treatment given that they may 
easily be confounded. Hence, it is essential to consider that ”depressive symptoms” 
may show different characteristics when examined for Type 1 Diabetes or Type 2 
Diabetes patients. Furthermore patient-doctor relationship in the therapeutic setting  
Table 2. Items scores comparison  
Table 1. Comparison of mean scores for total BDI score, per type of diabetes and 
adherence 
plays a crucial role, not only due to different clinical characteristics of Type 1 and Type 2 Diabetes but also because both the health care professional 
and the patient must be aware of its implications and treatment specificities in order to reinforce adherence. There is also the possibility that negative 
mood plays a mediating role mobilizing survival strategies that activate adherence. In this regard the development of an assessment instrument able 
to capture the emotional impact of diabetes specific features would be relevant in the future. 
